Josh Howell

Josh Howell

Board Member

Josh currently serves as the President & CEO of Life Link III, the largest provider of emergency air medical transportation services in the state of Minnesota, of which Allina Health is a founding consortium member.

A former EMT/Paramedic, Josh discovered a passion for cardiovascular care & intervention early in his career. As a son & grandson of patients successfully diagnosed and treated for cardiac arrhythmias, Josh recognizes the importance of support for continued, innovative research of cardiovascular injuries & disease. Josh strongly believes MHIF is a leader, internationally, in those very important efforts.

Josh holds graduate degrees in both Business Administration and Healthcare Administration, is a Fellow of the American College of Healthcare Executives (FACHE) and a Member/Certified Healthcare Financial Professional (CHFP) of the Healthcare Financial Management Association (HFMA).

Josh lives with his wife, Tara, and their three children in Elk River, MN.

Back to Board of Directors

Josh Howell
Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.